2,005 reports of this reaction
3.3% of all BELIMUMAB reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for BELIMUMAB, manufactured by GlaxoSmithKline LLC. There are 2,005 FDA adverse event reports linking BELIMUMAB to FATIGUE. This represents approximately 3.3% of all 60,128 adverse event reports for this drug.
Patients taking BELIMUMAB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among BELIMUMAB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for BELIMUMAB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,005 FDA reports for BELIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.3% of all adverse event reports for BELIMUMAB, making it one of the most commonly reported side effect.
If you experience fatigue while taking BELIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.